Clinical Trial Update: Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase II trial evaluating bevacizumab (R435) in combination with paclitaxel for inoperable metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (R435) (bevacizumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Chugai Pharmaceutical | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED